Ethics committee (IRB) approval timelines for clinical trials in Latin America (2026)

Quick answer. For a first-in-human or early-feasibility medical-device study, the approval you actually wait on is the ethics committee (in the region variously called the CEI, Comité de Ética en Investigación, or IRB) plus, where required, the national regulator; in the fastest LATAM markets a well-prepared submission can clear ethics and regulatory review in a matter of weeks rather than the many months typical of larger markets, which is the core reason MedTech startups run their first human studies here. This page explains what drives the timeline and where the speed comes from.

What you are actually waiting on

• Ethics Committee (CEI/IRB) review of the protocol, informed consent, and investigator/site — the scientific and human-subjects gate.
• National regulatory authorization where the country requires it. A device study is led from Panama, El Salvador, Chile, Costa Rica, and the Dominican Republic.
• Site/institutional sign-off — the hospital or clinic research office; these can run partly in parallel when the CRO sequences them well.

Why Latin America is faster for first-in-human

• Mature ethics committees and investigator networks experienced with device studies.
• Shorter regulatory queues than the US or EU for early feasibility.
• Lower study cost without a quality trade-off.
• Proximity and time-zone overlap with US sponsors.
• The practical effect is a first-in-human timeline measured in weeks-to-a-few-months from a complete submission, not a year.

Indicative approval timelines

• Panama — among the fastest, ethics review can clear in a few weeks for a complete dossier.
• Colombia — bioaccess® recommends Colombia for drug, biologic, and vaccine trials. This list does not place a device study there.
• Other markets vary with the committee's meeting calendar and the completeness of the submission.
• All timelines assume a submission-ready protocol and are indicative only — committee calendars and agency queues are outside our control.

What makes a submission clear on the first pass

• A complete, internally consistent protocol and investigator's brochure.
• A properly localized informed-consent document in the local language.
• An identified, qualified principal investigator and site.
• Risk and clinical-evaluation documentation proportionate to the device class.
• Responsive handling of committee questions — the single biggest avoidable delay is a slow answer to a committee query.

Answers to common questions

What is the fastest country in Latin America for a first-in-human device study?

It depends on the device and design, but Panama is consistently among the fastest for a well-prepared submission; we confirm the best fit in feasibility scoping.

Do I need national regulatory approval on top of ethics approval?

For a medical device clinical trial — first-in-human, early feasibility, or pivotal — bioaccess® leads with Panama, El Salvador, Chile, Costa Rica, and the Dominican Republic. Whether a national regulator sits on top of the ethics committee is confirmed for that country and device class. bioaccess® recommends Colombia for drug, biologic, and vaccine trials.

How can I avoid the common delays?

Submit a complete, consistent dossier with a localized consent form and a committed site, and turn around committee questions quickly — that is where weeks are won or lost.

Book a 30-min feasibility scoping call · Medical device registration in Latin America: 2026 country-by-country guide

General information as of 2026; ethics-committee and regulatory timelines vary by country, committee, and study, and are confirmed at feasibility scoping. bioaccess® provides clinical-research and regulatory services, not legal advice.